Last reviewed · How we verify
Poisoning by iron AND/OR its compounds — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Desferal | DEFEROXAMINE | Mitem Pharma | Iron Chelator | Deoxyhypusine hydroxylase | 1968-01-01 | |
| desferrioxamine | desferrioxamine | Brigham and Women's Hospital | Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Brigham and Women's Hospital · 1 drug in Poisoning by iron AND/OR its compounds
- Mitem Pharma · 1 drug in Poisoning by iron AND/OR its compounds
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Poisoning by iron AND/OR its compounds:
- Poisoning by iron AND/OR its compounds treatment updates — RSS
- Poisoning by iron AND/OR its compounds treatment updates — Atom
- Poisoning by iron AND/OR its compounds treatment updates — JSON
Cite this brief
Drug Landscape (2026). Poisoning by iron AND/OR its compounds — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/poisoning-by-iron-and-or-its-compounds. Accessed 2026-06-10.
Related
- Poisoning by iron AND/OR its compounds full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing